2024
Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis
Anabtawi N, Pasala M, Grimshaw A, Kharel P, Bal S, Godby K, Siwakoti A, Buford T, Bhatia S, Costa L, Williams G, Giri S. Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1084-1093. PMID: 38558541, PMCID: PMC11154774, DOI: 10.1002/jcsm.13446.Peer-Reviewed Original ResearchConceptsLow skeletal muscle massNon-relapse mortalityProgression free survivalTreatment-related toxicityHaematological malignanciesOverall survivalSkeletal muscle massMuscle massEffects of low skeletal muscle massImpact of low skeletal muscle massIncreased risk of treatment-related toxicityPresence of low skeletal muscle massRisk of treatment-related toxicityHazard ratioAssociated with worse survival outcomesAssociated with worse OSDerSimonian-Laird random-effects modelModerate heterogeneityInferior overall survivalWorse survival outcomesConfidence intervalsRandom-effects modelFree survivalSolid malignanciesPre-published protocolDigital Health Interventions for Hypertension Management in US Populations Experiencing Health Disparities
Katz M, Mszar R, Grimshaw A, Gunderson C, Onuma O, Lu Y, Spatz E. Digital Health Interventions for Hypertension Management in US Populations Experiencing Health Disparities. JAMA Network Open 2024, 7: e2356070. PMID: 38353950, PMCID: PMC10867699, DOI: 10.1001/jamanetworkopen.2023.56070.Peer-Reviewed Original ResearchConceptsDigital health interventionsHealth disparitiesHealth interventionsSystematic reviewSystolic BPSocial determinants of healthHypertension managementCommunity health workersFactors associated with cardiovascular diseaseDeterminants of healthLeveraging digital healthRemote BP monitoringDigital health technologiesStandard care groupMeta-analysisBlood pressureDiastolic BPPreferred Reporting ItemsControl groupSystolic BP changeBaseline to 6Random-effects modelSkilled nursingCultural tailoringSocial determinants
2023
Burden of bone disease in chronic pancreatitis: A systematic review and meta-analysis
Chhoda A, Hernandez-Woodbine M, Addo N, Nasir S, Grimshaw A, Gunderson C, Ahmed A, Freedman S, Sheth S. Burden of bone disease in chronic pancreatitis: A systematic review and meta-analysis. World Journal Of Gastroenterology 2023, 29: 1374-1394. PMID: 36925454, PMCID: PMC10011962, DOI: 10.3748/wjg.v29.i8.1374.Peer-Reviewed Original ResearchConceptsPrevalence of osteopeniaChronic pancreatitisFragility fracturesBone diseaseCP patientsClinical featuresPooled prevalenceSystematic reviewBaseline clinical featuresSignificant bone diseasePrevalence of osteoporosisBody mass indexCause of morbidityBone mineralization parametersRandom-effects modelPaucity of dataWeb of SciencePERT useSmoking exposureSystemic inflammationTherapy useMass indexTrue burdenCochrane LibraryMean ageThe global prevalence of human fascioliasis: a systematic review and meta-analysis
Infantes L, Yataco G, Ortiz-Martínez Y, Mayer T, Terashima A, Franco-Paredes C, Gonzalez-Diaz E, Rodriguez-Morales A, Bonilla-Aldana D, Barahona L, Grimshaw A, Chastain D, Sillau S, Marcos L, Henao-Martínez A. The global prevalence of human fascioliasis: a systematic review and meta-analysis. Therapeutic Advances In Infectious Disease 2023, 10: 20499361231185413. PMID: 37434654, PMCID: PMC10331341, DOI: 10.1177/20499361231185413.Peer-Reviewed Original ResearchHuman fascioliasisHigh prevalenceGlobal prevalenceSystematic reviewTropical diseasesLarger study sample sizeFollowing inclusion criteriaRandom-effects modelAppropriate diagnostic methodologyHigher prevalence estimatesWorld Health OrganizationRetrospective cohortCase seriesPooled prevalenceSignificant morbiditySubgroup analysisDisease burdenPrevalence proportionsClinical trialsJBI SUMARIWorldwide prevalenceStudy sample sizeInclusion criteriaMethodological qualityGeneral population
2022
Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis
Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, Rao SV, Nanna MG. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. American Heart Journal 2022, 251: 101-114. PMID: 35654162, PMCID: PMC10904033, DOI: 10.1016/j.ahj.2022.05.019.Peer-Reviewed Original ResearchConceptsMonths of DAPTHazard ratioIschemic eventsDuration of DAPTSelect patient characteristicsDual antiplatelet therapyAcute coronary syndromeCoronary artery lesionsPercutaneous coronary interventionConfidence intervalsAssociation of outcomesRandom-effects modelComprehensive literature searchMeta-regression analysisMajor bleedingAntiplatelet therapyCoronary syndromeArtery lesionsCoronary interventionControlled TrialsPatient characteristicsPrespecified outcomesGreater proportionSimilar efficacySystematic reviewBenefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis
Chhoda A, Singh S, Sheth AH, Grimshaw AA, Gunderson C, Sharma P, Kunstman JW, Sharma A, Ahuja N, Gonda TA, Farrell JJ. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis. Clinical Gastroenterology And Hepatology 2022, 21: 1430-1446. PMID: 35568304, DOI: 10.1016/j.cgh.2022.04.025.Peer-Reviewed Original ResearchConceptsDisease-specific mortalityAdvanced neoplasiaBD-IPMNsExtended surveillancePooled incidenceWorrisome featuresSystematic reviewIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmHigh-quality studiesRandom-effects modelWarrants further investigationWeb of ScienceNeoplasia incidenceWarrants further explorationSurvival benefitCochrane LibraryMucinous neoplasmsPancreatic cancerPancreatic cystsSurveillance periodEligible studiesOvid MEDLINELower incidenceSARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis
Conway R, Grimshaw AA, Konig MF, Putman M, Duarte‐García A, Tseng LY, Cabrera DM, Chock YPE, Degirmenci HB, Duff E, Egeli BH, Graef ER, Gupta A, Harkins P, Hoyer BF, Jayatilleke A, Jin S, Kasia C, Khilnani A, Kilian A, Kim AHJ, Lin CMA, Low C, Proulx L, Sattui SE, Singh N, Sparks JA, Tam H, Ugarte‐Gil M, Ung N, Wang K, Wise LM, Yang Z, Young KJ, Liew JW, Grainger R, Wallace ZS, Hsieh E, Alliance T. SARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis. Arthritis & Rheumatology 2022, 74: 766-775. PMID: 34807517, PMCID: PMC9011807, DOI: 10.1002/art.42030.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionMechanical ventilationRisk ratioOdds ratioMortality rateCOVID-19 disease severityJoanna Briggs Institute critical appraisal toolsCOVID-19Odds of hospitalizationNewcastle-Ottawa ScaleCOVID-19 outcomesRandom-effects modelCritical appraisal toolMantel-Haenszel formulaSystematic literature reviewAdjusted riskICU admissionRMD patientsClinical outcomesRheumatic diseasesMethodologic qualityRelative riskObservational studyGeneral populationLower risk
2021
Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis
Chhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, Sharma A, Ahuja N, Kastrinos F, Farrell JJ. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology 2021, 162: 786-798. PMID: 34813861, DOI: 10.1053/j.gastro.2021.11.021.Peer-Reviewed Original ResearchConceptsLate-stage PDACPancreatic ductal adenocarcinomaHigh-risk individualsHigh-grade precursorsCumulative incidenceAdvanced neoplasiaLate-stage pancreatic cancerTiming of presentationRandom-effects modelWeb of ScienceClinicoradiologic factorsClinicoradiologic featuresSurveillance imagingCochrane LibraryPancreatic cancerDuctal adenocarcinomaPancreatic morphologySurveillance studyFunnel plotLesion sitePDAC stagesSurveillance adherenceSystematic reviewMeta-AnalysisSignificant associationAntiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy
Zakko A, Zakko L, Grimshaw AA, Laine L. Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy. Digestive Diseases And Sciences 2021, 67: 4161-4169. PMID: 34796411, DOI: 10.1007/s10620-021-07302-w.Peer-Reviewed Original ResearchConceptsEndoscopic retrograde cholangiopancreatographyPost-sphincterotomy bleedingAntiplatelet monotherapyInclusion criteriaRisk of bleedingROBINS-I toolNewcastle-Ottawa ScaleHigh-quality studiesRandom-effects modelBackgroundClinical guidelinesAntithrombotic therapyAdult patientsCohort studyEndoscopic sphincterotomyPrimary outcomeAntiplatelet agentsOvid EmbaseRetrograde cholangiopancreatographyCochrane LibraryOvid MEDLINEMonotherapyMethodological qualityBleedingUnique citationsPatientsHypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects modelImmune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsDiarrhea/colitisICI therapyCheckpoint inhibitorsObservational studyAnti-programmed cell death-1/Outcomes of ICISystematic reviewCell death-1/Permanent ICI discontinuationReal-world incidenceRemission of diarrheaRecurrence of symptomsDeath-1/Treatment of diarrheaRandom-effects modelICI discontinuationAdvanced malignanciesAppropriate patientsPrimary outcomeOverall incidenceAntigen-4Early treatmentColitisHigh riskEvaluation of diagnostic yield of EUS among patients with asymptomatic common bile duct dilation: systematic review and meta-analysis
Chhoda A, Dawod S, Grimshaw A, Gunderson C, Mahadev S. Evaluation of diagnostic yield of EUS among patients with asymptomatic common bile duct dilation: systematic review and meta-analysis. Gastrointestinal Endoscopy 2021, 94: 890-901.e8. PMID: 34245751, DOI: 10.1016/j.gie.2021.07.002.Peer-Reviewed Original ResearchConceptsCommon bile duct dilationBile duct dilationAsymptomatic patientsBiliary dilationDiagnostic yieldCBD dilationDuct dilationEUS evaluationSystematic reviewHealth resource utilizationInverse variance methodRandom-effects modelCost-effectiveness analysisRadiologic evidenceBenign etiologyMalignant etiologyFrequent indicationOvid EmbaseAsymptomatic individualsCochrane LibraryMalignant pathologyOvid MEDLINEFurther interventionPatientsGoogle ScholarOutcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model
2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting ItemsEfficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsMultiple myelomaTreatment optionsPhase II/IIICumulative ranking (SUCRA) probabilitiesFirst-line treatmentHematopoietic cell transplantationTerms of efficacyRandom-effects modelEfficacious regimensFrailty biomarkersFrontline regimensThalidomide maintenanceEffective regimensGeriatric assessmentLine treatmentTreatment regimensCell transplantationMeeting libraryIndividual patientsToxicity profileRegimensPatientsSystematic reviewRanking probabilityEfficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Usmani S, Facon T, Moreau P, Dimopoulos M, Mateos M, Costa L. Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. Journal Of Clinical Oncology 2020, 38: 8540-8540. DOI: 10.1200/jco.2020.38.15_suppl.8540.Peer-Reviewed Original ResearchHigh-risk cytogeneticsProgression-free survivalPhase III trialsMultiple myelomaR settingIII trialsMature overall survival dataDerSimonian-Laird random-effects modelPhase III randomized trialsRandomized phase III trialFirst-line settingOverall survival dataImproved response ratesRandom-effects modelLog hazard ratioBackbone regimenBackbone regimensHRC patientsRefractory settingPrimary endpointSame regimenFree survivalCytogenetic riskMM patientsRandomized trialsRate of Preventable Mortality in Hospitalized Patients: a Systematic Review and Meta-analysis
Rodwin BA, Bilan VP, Merchant NB, Steffens CG, Grimshaw AA, Bastian LA, Gunderson CG. Rate of Preventable Mortality in Hospitalized Patients: a Systematic Review and Meta-analysis. Journal Of General Internal Medicine 2020, 35: 2099-2106. PMID: 31965525, PMCID: PMC7351940, DOI: 10.1007/s11606-019-05592-5.Peer-Reviewed Original ResearchConceptsInpatient deathPreventable mortalityPreventable deathsMortality rateHospital mortality rateLife expectancyRandom-effects modelSystematic literature searchNumber of deathsWeb of ScienceHospital deathAdult patientsHospitalized patientsResultsSixteen studiesCase seriesPooled rateCochrane LibraryInclusion criteriaPatientsMeta-AnalysisSystematic reviewLiterature searchData extractionMortalityDeath